Q2 EPS Estimate for Agilent Technologies Reduced by Analyst

Agilent Technologies, Inc. (NYSE:A - Free Report) - Stock analysts at Leerink Partnrs reduced their Q2 2025 EPS estimates for Agilent Technologies in a research note issued on Wednesday, April 16th. Leerink Partnrs analyst P. Souda now forecasts that the medical research company will earn $1.25 per share for the quarter, down from their prior forecast of $1.27. The consensus estimate for Agilent Technologies' current full-year earnings is $5.54 per share. Leerink Partnrs also issued estimates for Agilent Technologies' Q3 2025 earnings at $1.40 EPS, Q4 2025 earnings at $1.53 EPS, FY2025 earnings at $5.49 EPS, FY2026 earnings at $5.90 EPS and FY2027 earnings at $6.47 EPS.

Other equities analysts also recently issued reports about the company. Barclays cut their target price on Agilent Technologies from $138.00 to $115.00 and set an "equal weight" rating for the company in a research note on Thursday, April 10th. StockNews.com upgraded shares of Agilent Technologies from a "hold" rating to a "buy" rating in a research note on Tuesday, December 24th. Robert W. Baird decreased their price target on Agilent Technologies from $161.00 to $159.00 and set an "outperform" rating on the stock in a research note on Thursday, February 27th. Jefferies Financial Group dropped their price target on Agilent Technologies from $135.00 to $116.00 and set a "hold" rating for the company in a research report on Monday. Finally, TD Cowen lifted their target price on shares of Agilent Technologies to $135.00 and gave the stock a "buy" rating in a research report on Thursday, April 10th. Seven research analysts have rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $143.00.

Agilent Technologies Stock Performance

A traded up $3.17 during trading on Friday, hitting $105.98. The stock had a trading volume of 1,139,059 shares, compared to its average volume of 1,864,126. Agilent Technologies has a twelve month low of $96.43 and a twelve month high of $155.35. The company has a debt-to-equity ratio of 0.56, a quick ratio of 1.66 and a current ratio of 2.20. The company's 50-day moving average price is $118.12 and its 200 day moving average price is $131.80. The firm has a market capitalization of $30.21 billion, a P/E ratio of 24.36, a PEG ratio of 2.83 and a beta of 1.19.

Agilent Technologies (NYSE:A - Get Free Report) last posted its earnings results on Wednesday, February 26th. The medical research company reported $1.31 earnings per share for the quarter, beating the consensus estimate of $1.27 by $0.04. The business had revenue of $1.68 billion during the quarter, compared to the consensus estimate of $1.67 billion. Agilent Technologies had a return on equity of 25.56% and a net margin of 19.27%.

Agilent Technologies Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 23rd. Shareholders of record on Tuesday, April 1st will be given a $0.248 dividend. This represents a $0.99 dividend on an annualized basis and a dividend yield of 0.94%. The ex-dividend date is Tuesday, April 1st. Agilent Technologies's payout ratio is 22.76%.

Insider Transactions at Agilent Technologies

In other Agilent Technologies news, Director Daniel K. Podolsky sold 1,819 shares of the firm's stock in a transaction that occurred on Monday, March 31st. The shares were sold at an average price of $116.46, for a total value of $211,840.74. Following the sale, the director now owns 35,737 shares in the company, valued at approximately $4,161,931.02. This trade represents a 4.84 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, VP Rodney Gonsalves sold 1,908 shares of the firm's stock in a transaction that occurred on Monday, March 17th. The shares were sold at an average price of $121.98, for a total value of $232,737.84. Following the completion of the sale, the vice president now owns 21,786 shares in the company, valued at approximately $2,657,456.28. This represents a 8.05 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Flynn Zito Capital Management LLC lifted its holdings in shares of Agilent Technologies by 3.8% during the fourth quarter. Flynn Zito Capital Management LLC now owns 1,871 shares of the medical research company's stock valued at $251,000 after purchasing an additional 69 shares during the last quarter. IFP Advisors Inc raised its holdings in shares of Agilent Technologies by 17.7% during the fourth quarter. IFP Advisors Inc now owns 458 shares of the medical research company's stock valued at $62,000 after acquiring an additional 69 shares during the period. Tiemann Investment Advisors LLC boosted its stake in Agilent Technologies by 5.6% in the 4th quarter. Tiemann Investment Advisors LLC now owns 1,423 shares of the medical research company's stock worth $191,000 after purchasing an additional 75 shares during the period. Rothschild Investment LLC raised its stake in Agilent Technologies by 19.2% during the 4th quarter. Rothschild Investment LLC now owns 491 shares of the medical research company's stock valued at $66,000 after purchasing an additional 79 shares during the last quarter. Finally, CIBC Private Wealth Group LLC grew its position in Agilent Technologies by 1.2% in the 4th quarter. CIBC Private Wealth Group LLC now owns 7,479 shares of the medical research company's stock worth $1,025,000 after purchasing an additional 87 shares during the last quarter.

Agilent Technologies Company Profile

Agilent Technologies, Inc provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates in three segments: Life Sciences and Applied Markets, Diagnostics and Genomics, and Agilent CrossLab. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; and vacuum pumps, and measurement technologies.